WRF Capital — 2024 Investments
1 investments dated 2024 · listed companies and verified rows first · show all
Proniras Corporation is a clinical-stage biotechnology company developing novel small-molecule therapeutics for substance use disorders and specialty central nervous system (CNS) conditions, including treatments for opioid withdrawal and seizure disorders.
BiotechHealthtechSeattle, US
CHRISTOPHER TOOMBS(Executive Officer)LINDSAY RAYLE(Executive Officer, Promoter)M. Johnston Erwin(Director)David Schubert(Executive Officer, Promoter)
BoardSTEVEN GILLIS(Director)inThong Le(Executive Officer, Director, Promoter)
Co-investorsACCELERATOR LIFE SCIENCE PARTNERSARCH Venture Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.